UroGen Pharma Statistics
Total Valuation
UroGen Pharma has a market cap or net worth of $622.71 million. The enterprise value is $556.07 million.
| Market Cap | 622.71M |
| Enterprise Value | 556.07M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, before market open.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
UroGen Pharma has 41.13 million shares outstanding. The number of shares has increased by 43.38% in one year.
| Shares Outstanding | 41.13M |
| Shares Change (YoY) | +43.38% |
| Shares Change (QoQ) | +15.76% |
| Owned by Insiders (%) | 9.52% |
| Owned by Institutions (%) | 74.01% |
| Float | 22.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.39 |
| Forward PS | 5.68 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.47
| Current Ratio | 7.47 |
| Quick Ratio | 6.80 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.37 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -62.50% |
| Return on Capital (ROIC) | -119.17% |
| Revenue Per Employee | $413,245 |
| Profits Per Employee | -$511,358 |
| Employee Count | 204 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.39 |
Taxes
In the past 12 months, UroGen Pharma has paid $3.95 million in taxes.
| Income Tax | 3.95M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +49.75% in the last 52 weeks. The beta is 1.09, so UroGen Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +49.75% |
| 50-Day Moving Average | 14.38 |
| 200-Day Moving Average | 14.57 |
| Relative Strength Index (RSI) | 48.35 |
| Average Volume (20 Days) | 1,265,975 |
Short Selling Information
The latest short interest is 5.62 million, so 13.67% of the outstanding shares have been sold short.
| Short Interest | 5.62M |
| Short Previous Month | 5.26M |
| Short % of Shares Out | 13.67% |
| Short % of Float | 25.24% |
| Short Ratio (days to cover) | 7.30 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of $84.30 million and -$104.32 million in losses. Loss per share was -$3.34.
| Revenue | 84.30M |
| Gross Profit | 75.48M |
| Operating Income | -69.23M |
| Pretax Income | -100.36M |
| Net Income | -104.32M |
| EBITDA | -85.13M |
| EBIT | -86.76M |
| Loss Per Share | -$3.34 |
Balance Sheet
The company has $164.87 million in cash and $98.23 million in debt, giving a net cash position of $66.64 million or $1.62 per share.
| Cash & Cash Equivalents | 164.87M |
| Total Debt | 98.23M |
| Net Cash | 66.64M |
| Net Cash Per Share | $1.62 |
| Equity (Book Value) | -40.13M |
| Book Value Per Share | -0.98 |
| Working Capital | 170.42M |
Cash Flow
In the last 12 months, operating cash flow was -$82.30 million and capital expenditures -$171,000, giving a free cash flow of -$82.48 million.
| Operating Cash Flow | -82.30M |
| Capital Expenditures | -171,000 |
| Free Cash Flow | -82.48M |
| FCF Per Share | -$2.47 |
Margins
Gross margin is 89.53%, with operating and profit margins of -82.12% and -123.74%.
| Gross Margin | 89.53% |
| Operating Margin | -82.12% |
| Pretax Margin | -119.05% |
| Profit Margin | -123.74% |
| EBITDA Margin | -100.99% |
| EBIT Margin | -102.91% |
| FCF Margin | -97.83% |
Dividends & Yields
UroGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -43.38% |
| Shareholder Yield | -43.38% |
| Earnings Yield | -16.75% |
| FCF Yield | -13.24% |
Analyst Forecast
The average price target for UroGen Pharma is $42.88, which is 183.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $42.88 |
| Price Target Difference | 183.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 45.43% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
UroGen Pharma has an Altman Z-Score of -3.4 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.4 |
| Piotroski F-Score | 4 |